Guggenheim reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report issued on Friday ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential ...

William Blair has recently initiated Vigil Neuroscience Inc (VIGL) stock to Outperform rating, as announced on December 4, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had ...

Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a Phase 2 ...

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...

Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...

Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of ...

On Thursday, Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Demonstrated a favorable ...

Vigil Neuroscience (NASDAQ:VIGL – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on ...

Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...